Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 12

recruiting
3 968
countries
28
conditions
2 103

768 trials match your criteria

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

COVID-19

Recruiting

Study of Remdesivir to Prevent Severe COVID-19 in Kidney Transplant Recipients with No or Mild Symptoms

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remdesivir

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus

Rhinitis allergic+1

Recruiting

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.